Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

Chronic low-grade inflammation and neuronal deregulation are two components of a
smoldering disease activity that drives the progression of disability in people with multiple …

Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …

Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …

Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best
strategy to delay irreversible neurological damage and progression of multiple sclerosis …

This review addresses current changes in the approach to treating patients with multiple
sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment …

Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for
treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of …

Background High-efficacy disease-modifying therapies have been proven to slow disability
accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on …

The emergence of high-efficacy therapies for multiple sclerosis (MS), which target
inflammation more effectively than traditional disease-modifying therapies, has led to a shift …